Table 3. Cytotoxic effects of temozolomide (TMZ) and MG-132 alone or in combination on MGMT-positive GSC lines and the parental glioma cell lines.

Cell line	Growth inhibition rate (%)
	TMZ	MG-132	TMZ plus MG-132
U251	48.04 ± 1.00	15.49 ± 2.12	60.65 ± 2.49
U251G	17.48 ± 2.24	19.12 ± 4.27	62.99 ± 1.07
SKMG-4	45.06 ± 2.46	16.52 ± 4.73	57.28 ± 8.35
SKMG-4G	20.44 ± 2.95	20.69 ± 3.84	60.87 ± 4.87
SKMG-1	42.39 ± 1.60	15.41 ± 1.63	54.12 ± 2.07
SKMG-1G	19.33 ± 4.07	16.69 ± 1.79	57.02 ± 1.53
SF295	43.72 ± 2.62	16.30 ± 4.49	55.43 ± 4.35
SF295G	19.18 ± 0.68	19.08 ± 3.18	57.37 ± 3.20
U87	45.43 ± 2.97	21.08 ± 1.72	62.38 ± 3.11
U87G	21.16 ± 1.26	24.45 ± 2.12	33.94 ± 1.50

TMZ, temozolomide; GSC, glioma stem-like cell. Data are presented as mean ± standard deviation (SD) of 3 repeated experiments.